Zurich Cantonal Bank’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Zurich Cantonal Bank’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,928	Closed	-$87.9K	–	2901
2023 Q1	$87.9K	Buy	20,928 +2,824	+16%	+$14.7K	﹤0.01%	2359
2022 Q4	$109K	Buy	+18,104	New	+$98.8K	﹤0.01%	2218

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Zurich Cantonal Bank's CTIC Position: Q2 2023 in Review

Zurich Cantonal Bank sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 20,928 shares — an estimated $87.9K sold.

Zurich Cantonal Bank first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $109K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Zurich Cantonal Bank reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Zurich Cantonal Bank sold 20,928 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $87.9K.
Zurich Cantonal Bank first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Zurich Cantonal Bank's CTI BioPharma Corp. (DE) Common Stock position peaked at $109K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Zurich Cantonal Bank's 13F filing for Q2 2023, filed 7 Aug 2023.